Aldeyra Therapeutics (Aldeyra Therapeutics) EPS (Basic) : $-0.64 (TTM As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Aldeyra Therapeutics EPS (Basic)?

Aldeyra Therapeutics's basic earnings per share (Basic EPS) for the three months ended in Dec. 2023 was $-0.08. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.64.

Aldeyra Therapeutics's EPS (Diluted) for the three months ended in Dec. 2023 was $-0.08. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.64.

Aldeyra Therapeutics's EPS without NRI for the three months ended in Dec. 2023 was $-0.08. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2023 was -0.64.

During the past 3 years, the average EPS without NRI Growth Rate was 15.50% per year. During the past 5 years, the average EPS without NRI Growth Rate was 18.20% per year. During the past 10 years, the average EPS without NRI Growth Rate was 13.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Aldeyra Therapeutics's highest 3-Year average EPS without NRI Growth Rate was 27.60% per year. The lowest was -95.40% per year. And the median was 12.20% per year.

Aldeyra Therapeutics EPS (Basic) Historical Data

The historical data trend for Aldeyra Therapeutics's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aldeyra Therapeutics EPS (Basic) Chart

Aldeyra Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EPS (Basic)

Get a 7-Day Free Trial

-2.24

-1.11

-1.07

-1.06

-0.64

Aldeyra Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EPS (Basic)	Get a 7-Day Free Trial															-0.22	-0.27	-0.15	-0.14	-0.08

Aldeyra Therapeutics EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Aldeyra Therapeutics's Basic EPS for the fiscal year that ended in Dec. 2023 is calculated as

Basic EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-37.543	-	0)	/	58.943
	=	-0.64

Aldeyra Therapeutics's Basic EPS for the quarter that ended in Dec. 2023 is calculated as

Basic EPS (Q: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-4.753	-	0)	/	59.197
	=	-0.08

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.64

Aldeyra Therapeutics (NAS:ALDX) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Aldeyra Therapeutics EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Aldeyra Therapeutics's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Aldeyra Therapeutics (Aldeyra Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aldeyra Therapeutics Inc (NAS:ALDX) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

137:Germany 137:Germany

Address

131 Hartwell Avenue, Suite 320, Lexington, MA, USA, 02421

Website

https://www.aldeyra.com

Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer.

Executives

Perceptive Life Sciences Master Fund Ltd	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Todd C Brady	director, officer: President and CEO	C/O EVOKE PHARMA, INC., 505 LOMAS SANTA FE DRIVE, SOLANA BEACH CA 92075
Martin Joseph Joyce	director	1050 HINGHAM STREET, ROCKLAND MA 02370
Bruce Greenberg	officer: See Remarks	C/O ALDEYRA THERAPEUTICS, INC., 131 HARTWELL AVENUE, SUITE 320, LEXINGTON MA 02421
Stephen Machatha	officer: Chief Development Officer	131 HARTWELL AVENUE, SUITE 320, LEXINGTON MA 02421
Joseph Edelman	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Advisors Llc	10 percent owner	51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Richard Douglas	director	ONE KENDALL SQUARE, CAMBRIDGE MA 02139
Nancy Miller-rich	director	C/O INTERCEPT PHARMACEUTICALS, INC., 10 HUDSON YARDS, 37TH FL, NEW YORK NY 10001
Ben Bronstein	director	15 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803
David J Clark	officer: Chief Medical Officer	131 HARTWELL AVE, LEXINGTON MA 02421
David Mcmullin	officer: SVP Corp. Dev. & Strategy	C/O ALDEYRA THERAPEUTICS, INC., 131 HARTWELL AVENUE, SUITE 320, LEXINGTON MA 02421
Joshua Reed	officer: Chief Financial Officer	C/O ALDEYRA THERAPEUTICS, INC., 131 HARTWELL AVENUE, SUITE 320, LEXINGTON MA 02421
Jesse I Treu	director, 10 percent owner
Stephen J Tulipano	officer: Chief Financial Officer	C/O JAVELIN PHARMACEUTICALS, INC., 125 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140